Coronary Bifurcation Stenting (COBIS) Registry in South Korea (COBIS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00851526 |
Recruitment Status :
Completed
First Posted : February 26, 2009
Last Update Posted : July 17, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The COBIS registry is multi-center, real-world registry of drug-eluting stenting in coronary bifurcation lesions in South Korea.
The aim of the study was to find out the current status of bifurcation drug-eluting stenting and determine the prognostic factors for long-term outcome in South Korea.
Condition or disease |
---|
Coronary Bifurcation Lesion |
Study Type : | Observational |
Actual Enrollment : | 1919 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Coronary Bifurcation Stenting (COBIS) Registry in South Korea |
Study Start Date : | January 2004 |
Actual Primary Completion Date : | December 2008 |
Actual Study Completion Date : | December 2008 |
Group/Cohort |
---|
Coronary bifurcation lesion |
- Incidence of the composite outcome of all-cause death, MI, or any PCI/CABG [ Time Frame: 3 years ]
- Incidence of stent thrombosis, and periprocedural MI [ Time Frame: 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Age >= 18 years
- Any type of de novo bifurcation lesion with a parent vessel >= 2.5 mm and side branch>= 2.0 mm by visual estimation
- Treated with drug-eluting stent
Exclusion Criteria:
- Cardiogenic Shock
- ST elevation MI within 48hours
- Expected survival less than 1 year
- Left main bifurcation
- Allergy to the antiplatelets

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00851526
Korea, Republic of | |
Samsung Medical Center | |
Seoul, Korea, Republic of, 135-710 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Hyeon-Cheol Gwon, Professor, Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT00851526 History of Changes |
Other Study ID Numbers: |
2007-04-042 |
First Posted: | February 26, 2009 Key Record Dates |
Last Update Posted: | July 17, 2012 |
Last Verified: | July 2012 |
Coronary bifurcation lesion Drug-eluting stent |